US Stock Insider Trading | Sionna Therapeutics disclosed four insider transactions on February 4th

2026-02-19 04:54:20

On February 4, 2026, Sionna Therapeutics (SION) disclosed four insider trading transactions. Director Thompson Peter A. sold 29,100 shares on February 3, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 4, 2026	Director	ORBIMED ADVISORS LLC, Thompson Peter A.	February 3, 2026	Sell	58,100	44.58	2.5913 million
February 4, 2026	Director	ORBIMED ADVISORS LLC, Thompson Peter A.	February 2, 2026	Sell	3,780	44.57	168,500
January 26, 2026	Shareholder with >10% ownership	TPG GP A, LLC	January 22, 2026	Sell	250,000	40.00	10 million
December 29, 2025	Director	ORBIMED ADVISORS LLC, Thompson Peter A.	December 24, 2025	Sell	66,700	44.55	2.972 million
December 19, 2025	Director	ORBIMED ADVISORS LLC, Thompson Peter A.	December 19, 2025	Sell	1,950	44.49	86,800
December 19, 2025	Director	ORBIMED ADVISORS LLC, Thompson Peter A.	December 17, 2025	Sell	1,800	44.50	80,100
December 9, 2025	Executive	Fitzpatrick Jennifer	December 5, 2025	Sell	10,300	40.52	415,300
December 9, 2025	Executive	Fitzpatrick Jennifer	December 5, 2025	Buy	10,300	6.11	62,600
November 26, 2025	Director	ORBIMED ADVISORS LLC, Thompson Peter A.	November 26, 2025	Sell	3,200	44.49	142,400
November 26, 2025	Director	ORBIMED ADVISORS LLC, Thompson Peter A.	November 25, 2025	Sell	23,800	44.60	1.0606 million

[Company Information]

Sionna Therapeutics, Inc. was incorporated in Delaware in August 2019. The company is a clinical-stage biopharmaceutical company dedicated to developing novel drugs that normalize the function of cystic fibrosis transmembrane conductance regulator (CFTR) proteins, providing clinically meaningful benefits for CF patients and fundamentally changing the current treatment paradigm for cystic fibrosis patients.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes